Bias toward allopathic medicine in the research funding and publication of study results makes it difficult for physicians and others to find accurate data about the efficacy of non-Western, nonallopathic treatments.
Institutional review boards (IRBs) have the responsibility to ensure the protection of human-research subjects and are legally liable if they fail to do so.
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
Increased use of emergency departments for primary care puts undue burden on EDs; however, EMTALA obligates EDs to provide care to patients regardless of their ability to pay.